For laboratory research use only. Not for human or veterinary consumption.
Peptides & Coffee

Pancreas & adipose tissue: peptides in published research

Sources checked 2026-10-07 · 6 compounds · 9 cited studies

Scope: Pancreatic islets, HbA1c and body weight measures. Each entry names the model and the tissue that a published study looked at, with the citation. It describes what was studied, not what was found, and a listing here is not a claim that a compound does anything in that organ.

MOTS-c

  • Animal NOD mice (an autoimmune model); pancreatic islets and islet-infiltrating immune cells. Published 2021 · PubMed PMID 34320351 ↗

research profile · published study amounts · sources (shop page) · lab-tested lots

Also listed under: Liver, Muscle & tendon

Cagrilintide

  • Human Phase 2 trial at 57 sites in adults with a BMI of at least 30 (or at least 27 with hypertension or dyslipidaemia); bodyweight. Published 2021 · PubMed PMID 34798060 ↗

published study amounts · lab-tested lots

Retatrutide

  • Human Phase 2 trial in adults with a BMI of 30 or higher (or 27 to under 30 with a weight-related condition); body weight. Published 2023 · PubMed PMID 37366315 ↗
  • Human Phase 2 trial at 42 US centres in adults with HbA1c of 7.0-10.5% and BMI 25-50; HbA1c and body weight. Published 2023 · PubMed PMID 37385280 ↗

published study amounts · lab-tested lots

Also listed under: Liver

Semaglutide

  • Human STEP 1: 68-week double-blind trial in 1961 adults with a BMI of 30 or greater (27 or greater with a weight-related condition); change in body weight was a primary end point. Published 2021 · PubMed PMID 33567185 ↗

published study amounts · lab-tested lots

Also listed under: Heart & blood vessels, Liver, Kidney & urinary tract

Survodutide

published study amounts · lab-tested lots

Also listed under: Liver

Tirzepatide

  • Human SURMOUNT-1: 72-week trial in 2539 adults with a BMI of 30 or more (27 or more with a weight-related complication); body weight. Published 2022 · PubMed PMID 35658024 ↗
  • Human SURPASS-1: 40-week phase 3 trial in adults; the primary end point was change in HbA1c. Published 2021 · PubMed PMID 34186022 ↗

published study amounts · lab-tested lots

Also listed under: Heart & blood vessels, Liver

About this page

See also: all organ systems · all compound profiles.